Sugi Predict

Sugi Predict / Compounds / SCHEMBL1422182

SCHEMBL1422182

SCHEMBL1422182

COc1ccc(-c2ccccc2)cn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B1 P14061 1/20 0.67
▸ HSD17B2 P37059 1/20 0.67
▸ MKNK1 Q9BUB5 1/20 0.59
▸ MKNK2 Q9HBH9 1/20 0.59
▸ CYP2A6 P11509 2/20 0.58
▸ KDR P35968 2/20 0.57
▸ OXTR P30559 2/20 0.55
▸ NPC1 O15118 1/20 0.52
▸ LMNA P02545 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ PDGFRB P09619 1/20 0.51
▸ PDGFRA P16234 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ GRM5 P41594 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CASP1 P29466 1/20 0.49
▸ CHEK1 O14757 1/20 0.48
▸ ATR Q13535 1/20 0.48
▸ ADORA2A P29274 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31174412 0.89 CYP2A6 (0.68) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL3754419 0.89 CYP2A6 (0.68) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL1422493 0.83 MKNK1 (0.59) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL12497850 0.83 MKNK1 (0.59) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL1422588 0.82 CYP19A1 (0.65) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL577613 0.82 HSD17B1 (0.49) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL1422827 0.82 CYP19A1 (0.62) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL13575396 0.82 MKNK1 (0.57) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL13575351 0.82 MKNK1 (0.57) HSD17B1HSD17B2MKNK1MKNK2CYP2A6
SCHEMBL17742850 0.82 MKNK1 (0.57) HSD17B1HSD17B2MKNK1MKNK2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861365-B1 N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-07-01 — — EP claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
CN-105330595-B pyridine derivatives and their use as antimycobacterial agents 上海嘉坦医药科技有限公司 2019-12-10 — — CN disclosed
US-RE47142-E1 Compounds and methods for treating inflammatory and fibrotic disorders INTERMUNE, INC. (US) 2018-11-27 — — US disclosed
EP-3170810-B1 PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF CISEN PHARMACEUTICAL CO LTD (CN) 2018-09-19 — — EP disclosed
US-9878982-B2 Pyridine derivatives and anti-mycobacterial use thereof CISEN PHARMACEUTICAL CO., LTD. (CN) 2018-01-30 — — US disclosed
US-9878982-B2 Pyridine derivatives and anti-mycobacterial use thereof CISEN PHARMACEUTICAL CO., LTD. (CN) 2018-01-30 — — US disclosed
US-9878982-B2 Pyridine derivatives and anti-mycobacterial use thereof CISEN PHARMACEUTICAL CO., LTD. (CN) 2018-01-30 — — US disclosed
US-20170174628-A1 PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF CISEN PHARMACEUTICAL CO., LTD. (CN) 2017-06-22 — — US disclosed
US-20170174628-A1 PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF CISEN PHARMACEUTICAL CO., LTD. (CN) 2017-06-22 — — US disclosed
US-20090318455-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-24 — — US disclosed
US-20090318455-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-24 — — US disclosed
US-20090318455-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-24 — — US disclosed
WO-2009149188-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-10 — — WO disclosed
WO-2009149188-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-10 — — WO disclosed
US-20080015183-A1 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2008-01-17 — — US disclosed
CN-1260227-C 5-membered ring heterocyclic compounds with nitrogen TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-06-21 — — CN disclosed
CN-1413207-A 5-membered ring heterocyclic compounds with nitrogen TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-04-23 — — CN disclosed
EP-0711290-A1 METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1996-05-15 — — EP disclosed
WO-1995004052-A1 METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1995-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015183-A1 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES PIGS, HRH4, GPR88 HSD17B1 4241/4885HSD17B2 3672/4885MKNK1 2147/4885
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 HSD17B1 2861/4885HSD17B2 3058/4885MKNK1 167/4885
US-20170174628-A1 PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF ME3, SSBP1, MDH2 HSD17B1 3116/4885HSD17B2 3593/4885MKNK1 837/4885
US-20090318455-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS MAP3K8, MAP3K1, MAP3K6 HSD17B1 2178/4885HSD17B2 2354/4885MKNK1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.